| Name | Title | Contact Details |
|---|
Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. Ovid`s drug candidate, OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. Ovid has initiated the Phase 2 STARS trial of OV101 in adults with Angelman syndrome and a Phase 1 trial in adolescents with Angelman and Fragile X syndrome to identify doses suitable for younger patients.
Envision Healthcare, a leading national medical group, focused on investing in the future of health and wellness.
HealthTap is a technology company delivering a suite of connected health apps.
The Bright Spot for Health is a Wichita, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Johns Hopkins Healthcare is a Glen Burnie, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.